Board meeting for approval of basis of allotment for right issue
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr Lalchandani Labs Ltd has completed its rights issue, with the Board approving the allotment of 43,04,000 equity shares at ₹10 per share (face value), aggregating to ₹430.40 Lakhs. The rights issue opened on February 4, 2026, and closed on February 27, 2026, with full subscription as the entire 43.04 lakh shares were allotted. Post-allotment, the company's paid-up equity share capital has doubled from ₹4.33 crore (43.33 lakh shares) to ₹8.64 crore (86.37 lakh shares). The issue price being at face value means no premium was charged to existing shareholders.
The successful completion of the rights issue strengthens the company's capital base, doubling its equity capital. Since the issue was priced at face value, existing shareholders could subscribe at the most favorable price, though the dilutive effect of doubling the share count may pressure the stock price in the short term.